Slides: Rivaroxaban study points to cost savings

In an analysis of a subset of patients from the U.S. and Canada from the EINSTEIN-PE trial, Brahim Bookhart, director of Health Economics and Outcomes Research at Janssen Research & Development, and colleagues reported that patients who received rivaroxaban (Xarelto) had a shorter length of stay. That translated into savings of $2,040 per patient.

They presented their results Oct. 15 at the American College of Emergency Physicians meeting in Seattle.  

EINSTEIN found rivaroxaban, an oral factor Xa inhibitor, to be noninferior to standard therapy with enoxaparin in 4,832 patients who had acute symptomatic pulmonary embolism with or without deep-vein thrombosis.